V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230001572 | 230000925 | 1.73 | 60 | Palliative (P) | 2016-04-20 | 2016-04-21 | Rituximab (Maintenance) | 02 | N | 230010381 | IPILIMUMAB |
| 230001573 | 230001401 | 1.71 | 61 | Adjuvant (A) | 2017-10-08 | 2017-10-09 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 230011074 | GEMCITABINE |
| 230001574 | 230000931 | 1.74 | 92.8 | Not known (9) | 2014-08-28 | 2014-09-06 | Cetuximab 14 day | 2 | N | 230011482 | CISPLATIN + ETOPOSIDE + RT |
| 230001575 | 230000934 | 1.59 | 108.3 | Adjuvant (A) | 2018-12-28 | 2018-12-28 | TRASTUZUMAB | N | N | 230011728 | TRASTUZUMAB |
| 230001576 | 230000938 | 1.52 | 57.75 | Palliative (P) | 2017-08-31 | 2017-09-02 | Docetaxel 100mg/m2 (21 day) | 02 | N | 230012015 | IRINOTECAN + MDG |
| 230001577 | 230000940 | 1.82 | null | null | null | 2018-03-23 | Rituximab | N | N | 230012155 | RITUXIMAB |
| 230001578 | 230000943 | 1.8 | 92 | Palliative (P) | 2019-11-22 | 2019-12-05 | Temozolomide 200mg/m2 | N | N | 230012388 | CAPECITABINE + CISPLATIN + RT |
| 230001579 | 230001407 | 1.42 | 50.4 | Palliative (P) | 2016-09-20 | 2016-10-04 | Capecitabine | N | N | 230013331 | METHOTREXATE INTRATHECAL |
| 230001580 | 230000948 | 1.77 | 105.7 | Palliative (P) | 2016-03-28 | 2016-04-10 | Capecitabine | N | N | 230013481 | AZACITIDINE |
| 230001581 | 230000953 | 1.86 | 117.2 | Palliative (P) | 2018-08-13 | 2019-02-15 | Fluorouracil + Folinic Acid Weekly | null | N | 230013591 | TRASTUZUMAB |
| 230001582 | 230001409 | 1.63 | null | Curative (C) | 2018-02-17 | 2018-02-20 | Cisplatin + Pemetrexed | N | null | 230013808 | CARBOPLATIN |
| 230001583 | 230000956 | 1.76 | 69 | Adjuvant (A) | 2016-10-25 | 2017-03-11 | Sorafenib | N | N | 230013831 | CVP R |
| 230001584 | 230000957 | 1.55 | 93.6 | Curative (C) | 2018-12-22 | 2018-12-27 | Cisplatin | 02 | null | 230013848 | TRIAL |
| 230001585 | 230000957 | 1.59 | 73 | Adjuvant (A) | 2016-09-23 | 2017-04-01 | EC | N | N | 230013848 | PACLITAXEL |
| 230001586 | 230000957 | 1.9 | null | Neo-adjuvant (N) | 2017-06-17 | 2017-06-25 | Rituximab (Maintenance) | N | N | 230013848 | FLUOROURACIL + MITOMYCIN + RT |
| 230001587 | 230000959 | 1.67 | 67 | Palliative (P) | 2016-05-12 | 2016-05-13 | Oxaliplatin + Modified de Gramont | N | N | 230014179 | CARBOPLATIN + PACLITAXEL |
| 230001588 | 230000963 | null | null | Palliative (P) | null | 2017-03-26 | FLUOROURACIL + OXALIPLATIN | N | null | 230014410 | PACLITAXEL |
| 230001589 | 230000966 | 1.78 | 101.4 | Neo-adjuvant (N) | 2017-02-03 | 2017-02-06 | Cetuximab + Oxaliplatin + MdG Maint | N | N | 230014472 | FLUOROURACIL |
| 230001590 | 230000969 | null | 63.6 | Palliative (P) | 2017-06-19 | 2017-06-23 | PACLITAXEL | 02 | N | 230015009 | CVP R |
| 230001591 | 230000975 | 1.8 | 152 | Palliative (P) | 2014-11-08 | 2014-11-21 | FLUOROURACIL + IRINOTECAN | 02 | N | 230016462 | TRABECTEDIN |
| 230001592 | 230000982 | 1.7 | 86.9 | Palliative (P) | null | 2018-03-10 | Temozolomide 150mg/m2 | 02 | N | 230018373 | OXALIPLATIN + MDG |
| 230001593 | 230000982 | null | null | Adjuvant (A) | 2018-06-30 | 2018-07-05 | Docetaxel + Trastuzumab (Load) | N | N | 230018373 | TRABECTEDIN |
| 230001594 | 230000984 | 1.6 | 97.9 | Neo-adjuvant (N) | 2018-10-21 | 2019-01-11 | AFLIBERCEPT + FU + IRINOTECAN | 02 | N | 230019072 | LENVATINIB |
| 230001595 | 230000986 | 1.6 | null | Curative (C) | 2016-12-09 | 2016-12-14 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 230020135 | VANDETANIB |
| 230001596 | 230000988 | 1.78 | 82.8 | Adjuvant (A) | 2018-01-03 | 2018-01-03 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | 230020455 | RITUXIMAB |
| 230001597 | 230000992 | 1.59 | 71 | null | 2019-05-14 | 2019-05-14 | Cisplatin + Docetaxel +Fluorouracil | N | Y | 230021656 | TRIFLURIDINE + TIPIRACIL |
| 230001598 | 230000993 | null | 85 | Adjuvant (A) | 2016-03-21 | 2017-02-25 | Temozolomide 200mg/m2 | 02 | N | 230021833 | HYDROXYCARBAMIDE |
| 230001599 | 230001617 | 1.73 | 63.1 | Palliative (P) | 2019-10-13 | 2019-11-10 | Rituximab | 02 | N | 230021984 | FLUOROURACIL |
| 230001600 | 230000999 | 1.59 | 61.3 | Palliative (P) | 2015-08-01 | 2015-08-03 | CHOP R | null | null | 230023380 | LENVATINIB |
| 230001601 | 230001000 | 1.62 | 50.4 | Curative (C) | 2018-04-30 | 2018-07-08 | TRASTUZUMAB | 2 | N | 230023578 | DOCETAXEL + TRASTUZUMAB |
| 230001602 | 230001424 | 1.8 | null | Palliative (P) | 2018-08-19 | 2019-02-16 | Irinotecan + Modified De Gramont | 2 | N | 230023710 | OXALIPLATIN + MDG |
| 230001603 | 230001006 | 1.54 | null | Adjuvant (A) | 2013-12-28 | 2013-12-29 | Trastuzumab Subcutaneous | N | N | 230024026 | FEC + TRASTUZUMAB |
| 230001604 | 230001008 | 1.55 | 74.5 | Curative (C) | 2017-05-19 | 2017-05-27 | Rituximab (SUBCUTANEOUS Maintenance) | N | N | 230024332 | METHOTREXATE INTRATHECAL |
| 230001605 | 230001011 | 1.62 | 83.9 | Palliative (P) | 2016-11-26 | 2016-11-26 | CYCLOPHOSPHAMIDE | N | N | 230025230 | VANDETANIB |
| 230001606 | 230001012 | 1.61 | 83.3 | Neo-adjuvant (N) | 2018-01-11 | 2018-01-24 | Capecitabine | 02 | N | 230025262 | IPILIMUMAB |
| 230001607 | 230001016 | null | 85.2 | Palliative (P) | 2018-02-03 | 2018-03-01 | OXALIPLATIN + MDG + PANITUMUMAB | N | N | 230025405 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 230001608 | 230001020 | 1.52 | null | Adjuvant (A) | 2015-05-15 | 2015-05-15 | Trastuzumab 21 day maintenance | 02 | Y | 230025893 | VANDETANIB |
| 230001609 | 230001619 | 1.68 | 68.7 | Curative (C) | 2017-07-24 | 2017-08-15 | Trial Unspecified | N | N | 230026563 | PEMBROLIZUMAB |
| 230001610 | 230001619 | 1.53 | 74.5 | Adjuvant (A) | 2016-12-18 | 2016-12-18 | Capecitabine + Oxaliplatin 21day | 02 | null | 230026563 | MPT |
| 230001611 | 230001023 | 1.56 | 51.7 | Palliative (P) | 2016-03-22 | 2016-03-22 | VANDETANIB | 2 | N | 230027082 | DOCETAXEL |
| 230001612 | 230001029 | 1.85 | 69 | Palliative (P) | 2017-08-03 | 2017-09-01 | Carboplatin + Etoposide iv&po | 02 | N | 230028415 | TRIAL |
| 230001613 | 230001031 | 1.66 | 102.6 | Palliative (P) | 2017-10-25 | 2017-11-08 | LENVATINIB | 2 | N | 230001447 | OXALIPLATIN + MDG |
| 230001614 | 230001432 | 1.75 | 130.7 | null | 2014-11-09 | 2014-11-13 | Docetaxel 100mg/m2 (21 day) | N | N | 230001770 | DOCETAXEL |
| 230001615 | 230001033 | 1.77 | 69 | null | 2016-05-11 | 2016-05-11 | Enzalutamide | N | null | 230002211 | CABAZITAXEL |
| 230001616 | 230001036 | 1.72 | 85.2 | Adjuvant (A) | 2018-11-26 | 2018-11-27 | CETUXIMAB | N | N | 230003804 | CETUXIMAB + OXALIPLATIN + MDG |
| 230001617 | 230001038 | 1.73 | 89 | Palliative (P) | 2019-05-18 | 2019-06-09 | Bevacizumab + Oxaliplatin +MdG | N | N | 230004079 | CISPLATIN + GEMCITABINE |
| 230001618 | 230001043 | 1.64 | 67.75 | Adjuvant (A) | 2014-09-13 | 2014-11-30 | Oxaliplatin + Raltitrexed | N | N | 230011679 | RITUXIMAB |
| 230001619 | 230001044 | null | 89.3 | Palliative (P) | 2019-01-03 | 2019-01-03 | Irinotecan + Modified De Gramont | N | N | 230012425 | CAPECITABINE + OXALIPLATIN |
| 230001620 | 230001049 | 1.57 | 56.8 | Palliative (P) | 2014-11-09 | 2015-03-05 | Oxaliplatin + Modified de Gramont | N | Y | 230013595 | CVD |
| 230001621 | 230001051 | 1.6 | null | Adjuvant (A) | 2018-11-04 | 2018-11-22 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | 230014077 | CAPECITABINE + OXALIPLATIN |